Boston Scientific Corporation – Consensus Indicates Potential 6.1% Upside

Broker Ratings

Boston Scientific Corporation found using ticker (BSX) now have 25 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 53 and 45 with a mean TP of 48.92. With the stocks previous close at 46.12 this is indicating there is a potential upside of 6.1%. The day 50 moving average is 41.67 and the 200 day MA is 41.22. The company has a market capitalisation of $66,746m. Company Website: https://www.bostonscientific.com

The potential market cap would be $70,798m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Twitter
    LinkedIn
    Facebook
    Email
    Reddit

      AIM All Share Index